SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $206,658,499 |
| Positions | 16 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| KYVERNA THERAPEUTICS INC | KYTX | COM | $37,821,328 | 4,244,818 |
| PYXIS ONCOLOGY INC | PYXS | COMMON STOCK | $30,174,976 | 10,024,909 |
| TAYSHA GENE THERAPIES INC | TSHA | COM SHS | $24,501,508 | 723,185 |
| TEVA PHARMACEUTICAL INDS LTD | TEVA | SPONSORED ADS | $16,360,991 | 2,402,495 |
| VIR BIOTECHNOLOGY INC | VIR | COM | $13,792,695 | 1,353,552 |
| ALLOGENE THERAPEUTICS INC | ALLO | COM | $11,019,840 | 5,298,000 |
| CELLDEX THERAPEUTICS INC NEW | CLDX | COM NEW | $10,408,381 | 279,720 |
| EDITAS MEDICINE INC | EDIT | COM | $10,131,480 | 3,127,000 |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | COM | $9,653,082 | 289,101 |
| BAUSCH PLUS LOMB CORP | BLCO | COMMON SHARES | $9,496,696 | 573,472 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.